← All trials
NCT06272370
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2024
- Primary completion
- Jun 30, 2024
- Completion date
- Sep 30, 2024
- First posted
- Feb 22, 2024
- Last posted
- Feb 22, 2024
- Enrollment
- 125
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- DARTNet InstituteLead sponsor
- Harvard UniversityCollaborator
- University of Colorado, DenverCollaborator
- University of North Carolina at Chapel HillCollaborator
- University of WashingtonCollaborator
- Kelsey Research FoundationCollaborator
- Pennsylvania State UniversityOfficial
- Pennsylvania State UniversityCollaborator
- Reliant Medical GroupCollaborator
- RAND CorporationCollaborator
- Wake Forest UniversityCollaborator
- Rutgers UniversityCollaborator
- DARTNet InstituteOfficial
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.